149
Views
8
CrossRef citations to date
0
Altmetric
Clinical Features

Ceftaroline Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Obese Patients

, PharmD, MBA, , PharmD, DSc, , MD & , MD, MBA

References

  • . Genoni G, Prodam F, Marolda A, . Obesity and infection: two sides of one coin. Eur J Pediatr. 2014;173(1):25–32
  • . Huttunen R, Karppelin M, Syrjänen J. Obesity and nosocomial infections. J Hosp Infect. 2013;85(1):8–16
  • . Khawcharoenporn T, Tice AD, Grandinetti A, Chow D. Risk factors for community-associated methicillin-resistant Staphylococcus aureus cellulitis—and the value of recognition. Hawaii Med J. 2010;69(10):232–236
  • . Longo C, Bartlett G, Macgibbon B, . The effect of obesity on antibiotic treatment failure: a historical cohort study. Pharmacoepidemiol Drug Saf. 2013;22(9):970–976
  • . Al-Dorzi HM, Al Harbi SA, Arabi YM. Antibiotic therapy of pneumonia in the obese patient: dosing and delivery. Curr Opin Infect Dis. 2014;27(2):165–173
  • . Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother. 2008;52(9):3398–3407
  • . Kaushik D, Rathi S, Jain A. Ceftaroline: a comprehensive update. Int J Antimicrob Agents. 2011;37(5):389–395
  • . International Conference on Harmonisation E6 Good Clinical Practice guidance. Drug Information Branch (HFD-210), Center for Drug Evaluation and Research (CDER), 5600 Fishers Lane, Rockville, MD 20857. 1976. http://www.fda.gov/downloads/Drugs/Guidance/ucm073122.pdf
  • . Yosipovitch G, DeVore A, Dawn A. Obesity and the skin: skin physiology and skin manifestations of obesity. J Am Acad Dermatol. 2007;56(6):901–916
  • . Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. Int J Obes. 2013;37(3):333–340
  • . Gunderson CG. Cellulitis: definition, etiology, and clinical features. Am J Med. 2011;124(12):1113–1122
  • . Gunderson CG, Martinello RA. A systematic review of bacteremias in cellulitis and erysipelas. J Infect. 2012;64(2):148–155
  • . Guh DP, Zhang W, Bansback N, Amarsi Z, Laird Birmingham C, Amis AH. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 2009;9(Mar 25):88
  • . Ylitalo KR, Sowers M, Heeringa S. Peripheral vascular disease and peripheral neuropathy in individuals with cardiometabolic clustering and obesity. Diabetes Care. 2011;34(7):1642–1647
  • . File TM, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis. 2012;55( Suppl 3): S173–S180
  • . Stryjewski ME, Barriere SL, O'Riordan W, . Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections. J Antimicrob Chemother. 2012;67(6):1496–1502
  • . Pertel PE, Eisenstein BI, Link AS, . The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract. 2009;63(3):368–375
  • . Thadhani R, Tonelli M. Cohort studies: marching forward. Clin J Am Soc Nephrol. 2006;1(5):1117–1123

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.